A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biotechnology company, leveraging our proprietary cell expansion platform to develop scalable, cell-based solutions across the healthcare, food, and agriculture sectors. Through a collaborative network of ventures, we are advancing a diverse pipeline of products and services, including cultivated food, regenerative medicine, and cell-based ingredients. We have developed a unique three-dimensional (“3D”) technology platform for cell expansion with an industrial-scale cell manufacturing facility operated in accordance with Good Manufacturing Practice (“GMP”) standards, currently on a self-declared basis. We are utilizing our technology across the fields of regenerative medicine, immunotherapy, food tech, CDMO, and AgTech and plan to utilize it in industries and verticals that have a need for our mass scale and cost-effective cell expansion platform via partnerships, joint ventures, licensing agreements and other types of collaborations.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.3M | - | - | - | - | - |
| Net Income | -26M | -23M | -21M | -28M | -41M | 50M |
| EPS | $-3.31 | $-3.56 | $-3.99 | $-6.24 | $-10.24 | $-141.60 |
| Free Cash Flow | -22M | -20M | -18M | -23M | -37M | -31M |
| ROIC | -518.0% | -57.3% | -86.6% | -76.8% | -79.7% | - |
| Gross Margin | 40.6% | - | - | - | - | - |
| Debt/Equity | 0.00 | -3.99 | 250.28 | 1.76 | 0.72 | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -25M | -22M | -22M | -27M | -42M | -51M |
| Operating Margin | -1857.9% | - | - | - | - | - |
| ROE | 0.0% | - | -21758.3% | -212.1% | -137.3% | - |
| Shares Outstanding | 10M | 6M | 5M | 5M | 4M | - |
Pluri Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Pluri Inc. (PLUR) has a 5-year average return on invested capital (ROIC) of -75.1%. This is below average and may indicate limited pricing power.
Pluri Inc. (PLUR) has a market capitalization of $34M. It is classified as a small-cap stock.
Pluri Inc. (PLUR) does not currently pay a regular dividend.
Pluri Inc. (PLUR) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Pluri Inc. (PLUR) generated $-20 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Pluri Inc. (PLUR) reported earnings per share (EPS) of $-3.56 in its most recent fiscal year.
The Ledger Terminal provides 14 years of financial data for Pluri Inc. (PLUR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Pluri Inc. (PLUR) has a book value per share of $-1.08, based on its most recent annual SEC filing.